The Vanderbilt Vaccine Research Program (VVRP) is dedicated to promoting and ensuring the safety of vaccines. We are one of six centers that are part of a national consortium evaluating vaccine safety through the CDC-sponsored Clinical Immunization Safety Assessment (CISA) Network.The primary goals of the network are to improve the scientific understanding of vaccine safety issues through research and to serve as a source of clinical expertise in the evaluation of adverse events following immunization.
Experts in vaccines and vaccine safety convene to discuss complex vaccine issues through the CISA service entitled Clinical Consult Case Review. This service is available to any provider concerned about a possible adverse event following a vaccination.
Contact us regarding vaccine safety question at;
The VVRP also participates in numerous CISA-sponsored studies evaluating specific medical conditions or vaccine safety in particular populations. Please see below to learn more.
There is increasing appreciation for how human genetic variation may affect the risk for medication-related and vaccine-related adverse events. While substantial research has been done on the genetic basis of medication safety, relatively little research has been done on the genetic basis of vaccine safety. Several current studies are evaluating this issue:
- Post-Vaccine Adverse Events. Establishment of a Centralized Repository of Biological Specimens. This study will create a registry of clinically significant adverse events and related clinical data, and a repository of biological specimens from patients who experienced serious vaccine adverse events (VAEs).
- Evaluation of Genetic Risk Factors for Guillain-Barré Syndrome (GBS) After Vaccination: GBS has been associated with influenza and MCV4 vaccines. Since GBS is rare, genetic predisposition may be an important contributing factor. This study will identify genes that may be associated with an increased risk of GBS after vaccination.
- The Genomics of Wheezing and Variable Immune Response After Influenza Vaccination in Children 6-59 Months of Age. Recent studies have shown that children's reaction to influenza vaccine may be controlled by certain genetic variants. This study will identify both genetic and non-genetic factors that can predict whether a person will have an adverse reaction to the flu vaccine.
- Rotavirus Vaccine. One study evaluating horizontal transmission of vaccine strain virus is currently underway.